is predicted to increase the exposure to eletriptan.
▶ Cobicistat is predicted to markedly increase the exposure to
▶ Eletriptan increases the risk of vasoconstriction when given
with ergotamine. Separate administration by 24 hours.r
▶ HIV-protease inhibitors are predicted to markedly increase the
exposure to eletriptan. Avoid.rStudy
▶ Idelalisib is predicted to markedly increase the exposure to
▶ Macrolides (clarithromycin) are predicted to markedly increase
the exposure to eletriptan. Avoid.rStudy
▶ Macrolides (erythromycin) moderately increase the exposure to
is predicted to increase the exposure to eletriptan.
▶ Abiraterone is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Eliglustat is predicted to increase the exposure to aliskiren.
▶ Antiarrhythmics (dronedarone, propafenone) are predicted to
increase the exposure to eliglustat. Avoid or adjust dose—
consult product literature.rStudy
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
▶ Antifungals, azoles (fluconazole, isavuconazole, itraconazole,
ketoconazole, posaconazole, voriconazole) are predicted to
increase the exposure to eliglustat. Avoid or adjust dose—
consult product literature.rStudy
▶ Eliglustat is predicted to increase the exposure to
▶ Aprepitant is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Eliglustat is predicted to increase the exposure to atomoxetine.
▶ Eliglustat is predicted to increase the exposure to beta blockers,
non-selective (propranolol). Adjust dose.oStudy
▶ Eliglustat is predicted to increase the exposure to beta blockers,
selective (metoprolol). Adjust dose.oStudy
is predicted to decrease the exposure to eliglustat.
▶ Bupropion is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to eliglustat. Avoid or adjust dose—
consult product literature.rStudy
▶ Cinacalcet is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Cobicistat is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Eliglustat is predicted to increase the exposure to colchicine.
Avoid or adjust colchicine dose, p. 1120.rTheoretical
▶ Crizotinib is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
1448 Efavirenz — Eliglustat BNF 78
▶ Eliglustat is predicted to increase the exposure to dabigatran.
increases the exposure to digoxin. Adjust dose.
▶ Duloxetine is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Eliglustat is predicted to increase the exposure to edoxaban.
is predicted to decrease the exposure to eliglustat.
▶ Enzalutamide is predicted to decrease the exposure to
▶ Eliglustat is predicted to increase the exposure to everolimus.
▶ Grapefruit juice is predicted to increase the exposure to
eliglustat. Avoid.rTheoretical
▶ HIV-protease inhibitors are predicted to increase the exposure
eliglustat. Avoid or adjust dose—consult product literature.
▶ Idelalisib is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Imatinib is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Eliglustat is predicted to increase the exposure to loperamide.
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the exposure to eliglustat. Avoid or adjust dose—
consult product literature.rStudy
▶ Mirabegron is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Mitotane is predicted to decrease the exposure to eliglustat.
▶ Moclobemide is predicted to increase the exposure to
. Avoid or adjust dose—consult product literature.
▶ Netupitant is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
is predicted to decrease the exposure to eliglustat.
▶ Nilotinib is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Quinolones (ciprofloxacin) are predicted to increase the
exposure to eliglustat. Avoid or adjust dose—consult product
▶ Rifampicin is predicted to decrease the exposure to eliglustat.
▶ Eliglustat is predicted to increase the exposure to sirolimus.
▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the
exposure to eliglustat. Avoid or adjust dose—consult product
▶ St John’s Wort is predicted to increase the exposure to
▶ Eliglustat is predicted to increase the exposure to taxanes
(paclitaxel). Adjust dose.oStudy
▶ Terbinafine is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Eliglustat is predicted to increase the exposure to tolterodine.
▶ Eliglustat is predicted to increase the exposure to topotecan.
▶ Eliglustat is predicted to increase the exposure to tricyclic
antidepressants (nortriptyline). Adjust dose.oTheoretical
Elotuzumab → see monoclonal antibodies
▶ Antacids decrease the absorption of eltrombopag. Eltrombopag
should be taken 2 hours before or 4 hours after
▶ Oral calcium salts decrease the absorption of eltrombopag.
Eltrombopag should be taken 2 hours before or 4 hours after
▶ Ciclosporin decreases the exposure to eltrombopag. Monitor
▶ Dairy products are predicted to decrease the absorption of
eltrombopag. Eltrombopag should be taken 2 hours before or
4 hours after dairy products.rTheoretical
▶ Iron (oral) is predicted to decrease the absorption of
eltrombopag. Eltrombopag should be taken 2 hours before or
4 hours after iron (oral).rTheoretical
▶ Eltrombopag is predicted to increase the concentration of
▶ Eltrombopag is predicted to increase the concentration of
▶ Rifampicin is predicted to decrease the exposure to
eltrombopag and eltrombopag is predicted to increase the
concentration of rifampicin.oTheoretical
▶ Oral selenium is predicted to decrease the absorption of
eltrombopag. Eltrombopag should be taken 2 hours before or
4 hours after selenium.rTheoretical
▶ SSRIs (fluvoxamine) are predicted to increase the exposure to
▶ Eltrombopag is predicted to increase the exposure to statins.
Monitor and adjust dose.oStudy
▶ Eltrombopag is predicted to increase the exposure to tenofovir
▶ Eltrombopag is predicted to increase the exposure to tenofovir
▶ Oral zinc is predicted to decrease the absorption of
eltrombopag. Eltrombopag should be taken 2 hours before or
4 hours after zinc.rTheoretical
▶ Antacids moderately decrease the exposure to elvitegravir.
Separate administration by at least 4 hours.oStudy
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the
concentration of elvitegravir. Avoid.rTheoretical
▶ Bosentan is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶ Elvitegravir is predicted to decrease the anticoagulant effect of
▶ Efavirenz is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶ Enzalutamide is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶ Elvitegravir markedly increases the exposure to grazoprevir.
▶ HIV-protease inhibitors (atazanavir, lopinavir) (boosted with
ritonavir) increase the concentration of elvitegravir. Refer to
▶ Mitotane is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶ Nevirapine is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶ Rifampicin is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶ St John’s Wort is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
Empagliflozin → see TABLE 14 p. 1378 (antidiabetic drugs), TABLE 8
Enalapril → see ACE inhibitors
Encorafenib → see TABLE 9 p. 1377 (QT-interval prolongation)
▶ Antiarrhythmics (dronedarone) are predicted to moderately
increase the exposure to encorafenib.oStudy → Also see
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to moderately increase the exposure to
encorafenib.oStudy → Also see TABLE 9 p. 1377
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to encorafenib. Avoid or
monitor.rStudy → Also see TABLE 9 p. 1377
▶ Aprepitant is predicted to moderately increase the exposure to
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
moderately increase the exposure to
BNF 78 Eliglustat — Encorafenib 1449
▶ Cobicistat is predicted to increase the exposure to encorafenib.
▶ Encorafenib is predicted to affect the exposure to combined
hormonal contraceptives.rTheoretical
▶ Crizotinib is predicted to moderately increase the exposure to
encorafenib.oStudy → Also see TABLE 9 p. 1377
▶ Encorafenib is predicted to increase the exposure to
▶ Enzalutamide is predicted to decrease the exposure to
▶ Grapefruit juice is predicted to increase the exposure to
▶ HIV-protease inhibitors are predicted to increase the exposure
to encorafenib. Avoid or monitor.rStudy → Also see
▶ Idelalisib is predicted to increase the exposure to encorafenib.
▶ Imatinib is predicted to moderately increase the exposure to
▶ Macrolides (clarithromycin) are predicted to increase the
exposure to encorafenib. Avoid or monitor.rStudy → Also
▶ Macrolides (erythromycin) are predicted to moderately increase
the exposure to encorafenib.oStudy → Also see TABLE 9
is predicted to decrease the exposure to encorafenib.
▶ Netupitant is predicted to moderately increase the exposure to
▶ Nilotinib is predicted to moderately increase the exposure to
encorafenib.oStudy → Also see TABLE 9 p. 1377
▶ Encorafenib is predicted to increase the exposure to
▶ Rifampicin is predicted to decrease the exposure to
▶ St John’s Wort is predicted to decrease the exposure to
Enoxaparin → see low molecular-weight heparins
▶ Iron (oral) is predicted to decrease the absorption of
. Separate administration by at least 2 hours.
▶ Entacapone increases the exposure to levodopa. Monitor side
effects and adjust dose.oStudy
▶ Entacapone is predicted to increase the exposure to
▶ Entacapone is predicted to increase the risk of elevated blood
pressure when given with monoamine-oxidase A and B
inhibitors, irreversible. Avoid.rTheoretical
▶ Entacapone is predicted to increase the risk of cardiovascular
No comments:
Post a Comment
اكتب تعليق حول الموضوع